Joint Academy Launches AI-Native MSK Platform, Reports $40M in 2025 Revenue and Three Consecutive Free Cash Flow Positive Quarters, and Announces Partnerships with Cigna, Circle Health Group, Haleon and Novo Nordisk

Joint Academy today announced the launch of its AI-native musculoskeletal care platform alongside continued profitable growth, reaching approximately $40M in revenue in 2025 and delivering three consecutive quarters of positive free cash flow.

For the first time, Joint Academy is licensing its AI-native platform directly to clinicians and healthcare providers, expanding beyond its established business as a virtual & hybrid MSK care provider for health plans, employers and healthcare systems.

The company also announced expanded partnerships with leading global healthcare organizations, including Cigna Healthcare, Circle Health Group UK, Haleon and Novo Nordisk.

Joint Academy has treated more than 250,000 patients across the United States, the United Kingdom and Sweden, and has built one of the world’s largest MSK datasets, containing more than 1 billion data points and supported by 40+ peer-reviewed studies.

Its nationwide partnership with Cigna Healthcare expands access to virtual MSK care across the United States, while its collaboration with Circle Health Group UK supports integrated NHS MSK pathways in the United Kingdom.

Joint Academy also announced outcomes from its NHS Highlands & Islands pilot, demonstrating that 7% of patients on surgical waiting lists chose to avoid surgery after completing virtual physical therapy treatment, delivering a 4x return on investment. Reducing orthopedic surgical waitlists has become one of the most significant political and healthcare challenges across both the United Kingdom and Sweden.

The company’s partnerships with Haleon and Novo Nordisk focus on combining virtual care, pharmacological treatment, obesity care, GLP-1 therapies and real-world evidence to improve MSK outcomes and generate novel clinical insights.

Joint Academy is also expanding its role as a technology-enabled CRO platform, helping life science companies run clinical studies and generate real-world evidence at a fraction of the traditional cost through its AI platform, longitudinal MSK dataset and integrated virtual care infrastructure.

“Musculoskeletal care has historically been fragmented, reactive and difficult to scale,” said Leif Dahlberg, co-founder and Chief Medical Officer of Joint Academy and Professor of Orthopedics. “By combining continuous care, AI and longitudinal real-world data, we can improve treatment, research and outcomes at a global scale while making high-quality care significantly more accessible and cost-effective with our partners.”